Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

The National Community Pharmacists Association (NCPA) appreciates the opportunity to provide comments to the Pharmacy Compounding Advisory Committee (PCAC), which provides advice to the Food and Drug Administration (FDA), in advance of the June 8, 2022 meeting. NCPA appreciates the opportunity to share our comments and perspective on the topics of discussion on the meeting agenda as we continue to work with PCAC and FDA on regulatory issues in drug compounding arising from the authority granted to the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA). NCPA greatly appreciates the opportunity to share our views on the substances being considered by the PCAC at their June 8 meeting. NCPA is committed to working with the FDA and other stakeholders on these important matters. Please contact me with any additional questions or clarification at steve.postal@ncpa.org or (703) 600-1178.

Filed on regulations.gov — full text not in the inline record.